ES2543853T3 - Actividad antitumoral del temsirolimus frente al carcinoma papilar de células renales - Google Patents

Actividad antitumoral del temsirolimus frente al carcinoma papilar de células renales Download PDF

Info

Publication number
ES2543853T3
ES2543853T3 ES08742616.9T ES08742616T ES2543853T3 ES 2543853 T3 ES2543853 T3 ES 2543853T3 ES 08742616 T ES08742616 T ES 08742616T ES 2543853 T3 ES2543853 T3 ES 2543853T3
Authority
ES
Spain
Prior art keywords
cell carcinoma
renal cell
temsirolimus
papillary renal
antitumor activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08742616.9T
Other languages
English (en)
Inventor
Gary Dukart
James Joseph Gibbons, Jr.
Anna Berkenblit
Jay Marshall Feingold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39619123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2543853(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2543853T3 publication Critical patent/ES2543853T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

El 42-éster de la rapamicina con el ácido 3-hidroxi-2-(hidroximetil)-2-metilpropiónico ( CCI-779) para su uso en el tratamiento del carcinoma papilar de células renales avanzado en un mamífero.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES08742616.9T 2007-04-10 2008-04-08 Actividad antitumoral del temsirolimus frente al carcinoma papilar de células renales Active ES2543853T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92275907P 2007-04-10 2007-04-10
US922759P 2007-04-10
PCT/US2008/004501 WO2008124125A1 (en) 2007-04-10 2008-04-08 Anti-tumor activity of temsirolimus in papillary renal cell cancer

Publications (1)

Publication Number Publication Date
ES2543853T3 true ES2543853T3 (es) 2015-08-24

Family

ID=39619123

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12153823.5T Active ES2586739T3 (es) 2007-04-10 2008-04-08 Actividad antitumoral del temsirolimus frente al carcinoma papilar de células renales
ES08742616.9T Active ES2543853T3 (es) 2007-04-10 2008-04-08 Actividad antitumoral del temsirolimus frente al carcinoma papilar de células renales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12153823.5T Active ES2586739T3 (es) 2007-04-10 2008-04-08 Actividad antitumoral del temsirolimus frente al carcinoma papilar de células renales

Country Status (23)

Country Link
US (1) US8791097B2 (es)
EP (5) EP2462934B1 (es)
JP (2) JP5908669B2 (es)
KR (2) KR20150002887A (es)
CN (2) CN105769861A (es)
AU (1) AU2008236621B2 (es)
CA (1) CA2681451C (es)
CL (1) CL2008001009A1 (es)
CY (2) CY1116492T1 (es)
DK (2) DK2462934T3 (es)
ES (2) ES2586739T3 (es)
HR (2) HRP20150678T1 (es)
HU (2) HUE029052T2 (es)
IL (1) IL200835A (es)
MX (1) MX2009010954A (es)
PA (1) PA8776101A1 (es)
PL (2) PL2144611T3 (es)
PT (2) PT2462934T (es)
RU (1) RU2501559C2 (es)
SI (2) SI2144611T1 (es)
TW (1) TW200901989A (es)
WO (1) WO2008124125A1 (es)
ZA (1) ZA200907063B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
EP2550964A1 (en) * 2011-07-26 2013-01-30 Universitat Pompeu-Fabra Temsirolimus for use in the prevention and/or treatment of a delta 9-tetrahydrocannabinol-induced anxiety disorder
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN108143732A (zh) * 2017-12-19 2018-06-12 江南大学 雷帕霉素和ω-3脂肪酸在制备治疗肾癌的药物中的用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
AR029160A1 (es) * 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
UA81265C2 (en) 2002-09-17 2007-12-25 Wyeth Corp Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
AU2004235395A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
JP4227649B2 (ja) 2003-08-07 2009-02-18 ワイス Ｃｃｉ−７７９の位置選択的合成
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer

Also Published As

Publication number Publication date
IL200835A0 (en) 2010-05-17
SI2144611T1 (sl) 2015-08-31
JP2010523660A (ja) 2010-07-15
PA8776101A1 (es) 2009-03-31
DK2462934T3 (en) 2016-08-15
ZA200907063B (en) 2011-03-30
HRP20160698T1 (hr) 2016-07-15
EP3398597A1 (en) 2018-11-07
CN105769861A (zh) 2016-07-20
SI2462934T1 (sl) 2016-07-29
EP2462934B1 (en) 2016-06-08
TW200901989A (en) 2009-01-16
CY1117701T1 (el) 2017-05-17
AU2008236621A1 (en) 2008-10-16
KR20150002887A (ko) 2015-01-07
CA2681451A1 (en) 2008-10-16
PT2462934T (pt) 2016-08-17
EP3248601A1 (en) 2017-11-29
HUE026022T4 (hu) 2017-09-28
JP2015083595A (ja) 2015-04-30
CN101678008A (zh) 2010-03-24
BRPI0809322A2 (pt) 2014-09-23
KR20090130040A (ko) 2009-12-17
EP3106164A1 (en) 2016-12-21
WO2008124125A1 (en) 2008-10-16
PL2462934T3 (pl) 2016-10-31
DK2144611T3 (en) 2015-08-10
AU2008236621B2 (en) 2013-06-27
IL200835A (en) 2015-09-24
CL2008001009A1 (es) 2008-10-17
HUE026022T2 (hu) 2016-05-30
JP5908669B2 (ja) 2016-04-26
EP2144611B9 (en) 2016-05-18
CA2681451C (en) 2016-08-02
RU2501559C2 (ru) 2013-12-20
HUE029052T2 (hu) 2017-01-30
KR101544222B1 (ko) 2015-08-12
EP2144611B1 (en) 2015-06-17
ES2586739T3 (es) 2016-10-18
RU2009134479A (ru) 2011-05-20
PL2144611T3 (pl) 2015-10-30
US8791097B2 (en) 2014-07-29
CY1116492T1 (el) 2017-03-15
EP2462934A1 (en) 2012-06-13
US20080255177A1 (en) 2008-10-16
PT2144611E (pt) 2015-09-11
EP2144611A1 (en) 2010-01-20
HRP20150678T1 (hr) 2015-08-14
MX2009010954A (es) 2009-10-29

Similar Documents

Publication Publication Date Title
WO2009032831A3 (en) Offset weight supporting slide
ES2633997T3 (es) Instalación para aparcamiento y recarga de vehículos eléctricos
AR031341A1 (es) Uso de cci-779 como agente antineoplastico
CL2011002739A1 (es) Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
ECSP13012692A (es) Compuestos tricíclicos inhibidores de la pi3k y métodos de uso
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
PA8643201A1 (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
EP2546721A3 (en) Flexible display with display support
WO2008019311A3 (en) Automated cassette and slide handling system for an automatic microscope
EP2605077A3 (en) Image forming apparatus
ES2534989T3 (es) Nuevos complejos de inclusión farmacéuticos sólidos solubles en agua y sus soluciones acuosas para uso oral, oftálmico, tópico o parenteral que contienen un macrólido y ciertas ciclodextrinas
ES2482168T3 (es) Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente
EP2594878A3 (en) Refrigerator
ES2532114T3 (es) Dispositivo automatizado para el cambio de raíl para railes aéreos soportados en el aire
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
ES2664171T3 (es) Aditivo retardador del fraguado y plastificante para el hormigón
AR066893A1 (es) Uso del factor de crecimiento de fibroblastos 7 (fgf7) y del receptor fgfr2b como biomarcadores
JP2010502177A5 (es)
WO2007056175A3 (en) 41-methoxy isotope labeled rapamycin 42-ester
PA8636101A1 (es) Metodo para la preparacion de acidos hidroxamicos
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
GT200600044A (es) Polimorfo cci-779 y su uso
GB201108994D0 (en) Perimeter screen system